Global Skin Infection Market
Global Skin Infection Market

Skin Infection Comprehensive Study by Type (Bacterial Skin Infection, Viral Skin Infection, Fungal Skin Infection, Parasitic Skin Infection), by Treatment Type (Traditional Treatment, Basic Treatment, Bio-Active Treatment, Therapeutic Treatment, Advanced Treatment), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and E-commerce, Drugstores, Others) Players and Region - Global Market Outlook to 2024

Skin Infection Market Segmented into XX Submarkets. | Forecast Years: 2020- 2025  

Mar 2019 Edition 240 Pages 166 Tables & Figures
Sample Report Speak with Analyst Request Discount
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Global Skin Infection Market Overview:
Skin infection generally caused by fungus, bacteria, parasites and virus. This infection can be mild or severe depending on the infecting agent. Some of the symptoms of skin infection are discoloring and breakdown of the skin, blood blister, pus and others. Patients with diabetics, AIDS and others diseases are more prone to skin infections as these diseases lower the immune system of an individual and can cause life-threatening consequences. Some of the key players profiled in the study are 3M Company (United States), B. Braun Melsungen (Germany), Coloplast (Denmark), Genzyme Corporation (United States), Smith & Nephew (United Kingdom), ConvaTec Healthcare (United States), Human Biosciences Inc. (United States) and Melinta Therapeutics, Inc. (United States).

On the basis of geography, the market of Skin Infection has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by by Treatment Type, the sub-segment i.e. Traditional Treatment will boost the Skin Infection market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by by Distribution Channel, the sub-segment i.e. Hospital Pharmacies will boost the Skin Infection market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Increasing Prevalence of Skin Infection Led to Growing Hygiene Awareness

Market Trend
  • Developments in Biotechnology and Tissue Engineering

Restraints
  • Stringent Regulatory Guidelines on Production and Trade of Skin Infection Products

Opportunities
  • Substandard Lifestyle and Poverty Led to Rise in Skin Infection Cases

Challenges
  • Growing Counterfeit Drugs Manufacturers
  • Use of Homemade Remedies to Counter Skin Infection in Emerging Countries



"In 2013 the US Food and Drug Administration (FDA) issued recommendations and guidance on developing drugs for the treatment of skin infection using a new definition of acute bacterial skin and skin-structure infection (ABSSSI). The new classification includes cellulitis, erysipelas, major skin abscesses and wound infection with a considerable extension of skin involvement, clearly referring to a severe subset of skin infections. The main goal of the FDA was to better identify specific infections where the advantages of a new antibiotic could be precisely estimated through quantifiable parameters, such as improvement of the lesion size and of systemic signs of infection."
Skin infection market is fragmented owing to the presence of numerous players in the market. Companies are gradually focusing on the technological development for novel products and techniques for advanced and timely treatment of the skin infections creating lucrative opportunities for the skin infection market.

Target Audience:
Healthcare Institute, Pharmaceutical Companies, Hospitals and Clinics, Drugs Manufacturers, Government bodies, Market research firms, Research Institutes and Others

Major Objectives Focused through this Study
• To define, describe, and forecast the Global Skin Infection market on the basis of product [Bacterial Skin Infection, Viral Skin Infection, Fungal Skin Infection and Parasitic Skin Infection] , application [], key regions and end user
• To provide in-depth information regarding major influencing factors affecting the growth of the market (trends, drivers, restraints, opportunities, and industry-centric and regional challenges)
• To strategically analyse the micro-markets and important business segments with respect to individual growth drivers , market trends and potential, and historical contributions to the total market
• Identifying the opportunities in the market for key stakeholders and detailing the competitive landscape for market leaders
• To provide market size for various segments of the Skin Infection market with respect to major geographies, namely, South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico)
• To strategically profile the key players and analyzing their market shares and core competencies in the Skin Infection industry
• To track key developments such as product launches, expansions, agreements, partnerships, mergers & acquisitions, and R&D activities that are key factors in shaping the market

Available Customization:
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**. Additionally, the Players which are also part of the research are Merck & Co., Inc. (United States), Allergan plc (United States) and Accord Healthcare Ltd. (United Kingdom).
** Confirmation on availability of data would be informed prior purchase

While framing the research framework, major and emerging players operating in the Skin Infection market in various regions have been profiled, and their offerings, geographic footprints, and distribution/sales channels have been analysed through in-depth discussions. Top-down and bottom-up approaches have been used to determine the overall market size. Sizes of the other individual markets have been estimated using the percentage splits obtained through secondary sources such as Hoovers, Bloomberg BusinessWeek, and Dow Jones (Factiva), along with primary respondents. The complete methodology includes the study of the annual and financial reports of the key market players and extensive interviews with industry experts such as CEOs, VPs, directors, and marketing executives for key insights (both qualitative and quantitative) related to the market.
Report Objectives / Segmentation Covered
By Type
  • Bacterial Skin Infection
  • Viral Skin Infection
  • Fungal Skin Infection
  • Parasitic Skin Infection
By by Treatment Type
  • Traditional Treatment
  • Basic Treatment
  • Bio-Active Treatment
  • Therapeutic Treatment
  • Advanced Treatment

By by Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies and E-commerce
  • Drugstores
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Prevalence of Skin Infection Led to Growing Hygiene Awareness
    • 3.3. Market Challenges
      • 3.3.1. Growing Counterfeit Drugs Manufacturers
      • 3.3.2. Use of Homemade Remedies to Counter Skin Infection in Emerging Countries
    • 3.4. Market Trends
      • 3.4.1. Developments in Biotechnology and Tissue Engineering
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Skin Infection, by Type, by Treatment Type, by Distribution Channel and Region (value) (2013-2018)
    • 5.1. Introduction
    • 5.2. Global Skin Infection (Value)
      • 5.2.1. Global Skin Infection by: Type (Value)
        • 5.2.1.1. Bacterial Skin Infection
        • 5.2.1.2. Viral Skin Infection
        • 5.2.1.3. Fungal Skin Infection
        • 5.2.1.4. Parasitic Skin Infection
      • 5.2.2. Global Skin Infection Region
        • 5.2.2.1. South America
          • 5.2.2.1.1. Brazil
          • 5.2.2.1.2. Argentina
          • 5.2.2.1.3. Rest of South America
        • 5.2.2.2. Asia Pacific
          • 5.2.2.2.1. China
          • 5.2.2.2.2. Japan
          • 5.2.2.2.3. India
          • 5.2.2.2.4. South Korea
          • 5.2.2.2.5. Taiwan
          • 5.2.2.2.6. Australia
          • 5.2.2.2.7. Rest of Asia-Pacific
        • 5.2.2.3. Europe
          • 5.2.2.3.1. Germany
          • 5.2.2.3.2. France
          • 5.2.2.3.3. Italy
          • 5.2.2.3.4. United Kingdom
          • 5.2.2.3.5. Netherlands
          • 5.2.2.3.6. Rest of Europe
        • 5.2.2.4. MEA
          • 5.2.2.4.1. Middle East
          • 5.2.2.4.2. Africa
        • 5.2.2.5. North America
          • 5.2.2.5.1. United States
          • 5.2.2.5.2. Canada
          • 5.2.2.5.3. Mexico
  • 6. Skin Infection: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2018)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. 3M Company (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. B. Braun Melsungen (Germany)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Coloplast (Denmark)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Genzyme Corporation (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Smith & Nephew (United Kingdom)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. ConvaTec Healthcare (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Human Biosciences Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Melinta Therapeutics, Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
  • 7. Global Skin Infection Sale, by Type, by Treatment Type, by Distribution Channel and Region (value) (2019-2024)
    • 7.1. Introduction
    • 7.2. Global Skin Infection (Value)
      • 7.2.1. Global Skin Infection by: Type (Value)
        • 7.2.1.1. Bacterial Skin Infection
        • 7.2.1.2. Viral Skin Infection
        • 7.2.1.3. Fungal Skin Infection
        • 7.2.1.4. Parasitic Skin Infection
      • 7.2.2. Global Skin Infection Region
        • 7.2.2.1. South America
          • 7.2.2.1.1. Brazil
          • 7.2.2.1.2. Argentina
          • 7.2.2.1.3. Rest of South America
        • 7.2.2.2. Asia Pacific
          • 7.2.2.2.1. China
          • 7.2.2.2.2. Japan
          • 7.2.2.2.3. India
          • 7.2.2.2.4. South Korea
          • 7.2.2.2.5. Taiwan
          • 7.2.2.2.6. Australia
          • 7.2.2.2.7. Rest of Asia-Pacific
        • 7.2.2.3. Europe
          • 7.2.2.3.1. Germany
          • 7.2.2.3.2. France
          • 7.2.2.3.3. Italy
          • 7.2.2.3.4. United Kingdom
          • 7.2.2.3.5. Netherlands
          • 7.2.2.3.6. Rest of Europe
        • 7.2.2.4. MEA
          • 7.2.2.4.1. Middle East
          • 7.2.2.4.2. Africa
        • 7.2.2.5. North America
          • 7.2.2.5.1. United States
          • 7.2.2.5.2. Canada
          • 7.2.2.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Skin Infection: by Type(USD Million)
  • Table 2. Skin Infection Bacterial Skin Infection , by Region USD Million (2013-2018)
  • Table 3. Skin Infection Viral Skin Infection , by Region USD Million (2013-2018)
  • Table 4. Skin Infection Fungal Skin Infection , by Region USD Million (2013-2018)
  • Table 5. Skin Infection Parasitic Skin Infection , by Region USD Million (2013-2018)
  • Table 6. South America Skin Infection, by Country USD Million (2013-2018)
  • Table 7. South America Skin Infection, by Type USD Million (2013-2018)
  • Table 8. South America Skin Infection, by by Treatment Type USD Million (2013-2018)
  • Table 9. South America Skin Infection, by by Distribution Channel USD Million (2013-2018)
  • Table 10. Brazil Skin Infection, by Type USD Million (2013-2018)
  • Table 11. Brazil Skin Infection, by by Treatment Type USD Million (2013-2018)
  • Table 12. Brazil Skin Infection, by by Distribution Channel USD Million (2013-2018)
  • Table 13. Argentina Skin Infection, by Type USD Million (2013-2018)
  • Table 14. Argentina Skin Infection, by by Treatment Type USD Million (2013-2018)
  • Table 15. Argentina Skin Infection, by by Distribution Channel USD Million (2013-2018)
  • Table 16. Rest of South America Skin Infection, by Type USD Million (2013-2018)
  • Table 17. Rest of South America Skin Infection, by by Treatment Type USD Million (2013-2018)
  • Table 18. Rest of South America Skin Infection, by by Distribution Channel USD Million (2013-2018)
  • Table 19. Asia Pacific Skin Infection, by Country USD Million (2013-2018)
  • Table 20. Asia Pacific Skin Infection, by Type USD Million (2013-2018)
  • Table 21. Asia Pacific Skin Infection, by by Treatment Type USD Million (2013-2018)
  • Table 22. Asia Pacific Skin Infection, by by Distribution Channel USD Million (2013-2018)
  • Table 23. China Skin Infection, by Type USD Million (2013-2018)
  • Table 24. China Skin Infection, by by Treatment Type USD Million (2013-2018)
  • Table 25. China Skin Infection, by by Distribution Channel USD Million (2013-2018)
  • Table 26. Japan Skin Infection, by Type USD Million (2013-2018)
  • Table 27. Japan Skin Infection, by by Treatment Type USD Million (2013-2018)
  • Table 28. Japan Skin Infection, by by Distribution Channel USD Million (2013-2018)
  • Table 29. India Skin Infection, by Type USD Million (2013-2018)
  • Table 30. India Skin Infection, by by Treatment Type USD Million (2013-2018)
  • Table 31. India Skin Infection, by by Distribution Channel USD Million (2013-2018)
  • Table 32. South Korea Skin Infection, by Type USD Million (2013-2018)
  • Table 33. South Korea Skin Infection, by by Treatment Type USD Million (2013-2018)
  • Table 34. South Korea Skin Infection, by by Distribution Channel USD Million (2013-2018)
  • Table 35. Taiwan Skin Infection, by Type USD Million (2013-2018)
  • Table 36. Taiwan Skin Infection, by by Treatment Type USD Million (2013-2018)
  • Table 37. Taiwan Skin Infection, by by Distribution Channel USD Million (2013-2018)
  • Table 38. Australia Skin Infection, by Type USD Million (2013-2018)
  • Table 39. Australia Skin Infection, by by Treatment Type USD Million (2013-2018)
  • Table 40. Australia Skin Infection, by by Distribution Channel USD Million (2013-2018)
  • Table 41. Rest of Asia-Pacific Skin Infection, by Type USD Million (2013-2018)
  • Table 42. Rest of Asia-Pacific Skin Infection, by by Treatment Type USD Million (2013-2018)
  • Table 43. Rest of Asia-Pacific Skin Infection, by by Distribution Channel USD Million (2013-2018)
  • Table 44. Europe Skin Infection, by Country USD Million (2013-2018)
  • Table 45. Europe Skin Infection, by Type USD Million (2013-2018)
  • Table 46. Europe Skin Infection, by by Treatment Type USD Million (2013-2018)
  • Table 47. Europe Skin Infection, by by Distribution Channel USD Million (2013-2018)
  • Table 48. Germany Skin Infection, by Type USD Million (2013-2018)
  • Table 49. Germany Skin Infection, by by Treatment Type USD Million (2013-2018)
  • Table 50. Germany Skin Infection, by by Distribution Channel USD Million (2013-2018)
  • Table 51. France Skin Infection, by Type USD Million (2013-2018)
  • Table 52. France Skin Infection, by by Treatment Type USD Million (2013-2018)
  • Table 53. France Skin Infection, by by Distribution Channel USD Million (2013-2018)
  • Table 54. Italy Skin Infection, by Type USD Million (2013-2018)
  • Table 55. Italy Skin Infection, by by Treatment Type USD Million (2013-2018)
  • Table 56. Italy Skin Infection, by by Distribution Channel USD Million (2013-2018)
  • Table 57. United Kingdom Skin Infection, by Type USD Million (2013-2018)
  • Table 58. United Kingdom Skin Infection, by by Treatment Type USD Million (2013-2018)
  • Table 59. United Kingdom Skin Infection, by by Distribution Channel USD Million (2013-2018)
  • Table 60. Netherlands Skin Infection, by Type USD Million (2013-2018)
  • Table 61. Netherlands Skin Infection, by by Treatment Type USD Million (2013-2018)
  • Table 62. Netherlands Skin Infection, by by Distribution Channel USD Million (2013-2018)
  • Table 63. Rest of Europe Skin Infection, by Type USD Million (2013-2018)
  • Table 64. Rest of Europe Skin Infection, by by Treatment Type USD Million (2013-2018)
  • Table 65. Rest of Europe Skin Infection, by by Distribution Channel USD Million (2013-2018)
  • Table 66. MEA Skin Infection, by Country USD Million (2013-2018)
  • Table 67. MEA Skin Infection, by Type USD Million (2013-2018)
  • Table 68. MEA Skin Infection, by by Treatment Type USD Million (2013-2018)
  • Table 69. MEA Skin Infection, by by Distribution Channel USD Million (2013-2018)
  • Table 70. Middle East Skin Infection, by Type USD Million (2013-2018)
  • Table 71. Middle East Skin Infection, by by Treatment Type USD Million (2013-2018)
  • Table 72. Middle East Skin Infection, by by Distribution Channel USD Million (2013-2018)
  • Table 73. Africa Skin Infection, by Type USD Million (2013-2018)
  • Table 74. Africa Skin Infection, by by Treatment Type USD Million (2013-2018)
  • Table 75. Africa Skin Infection, by by Distribution Channel USD Million (2013-2018)
  • Table 76. North America Skin Infection, by Country USD Million (2013-2018)
  • Table 77. North America Skin Infection, by Type USD Million (2013-2018)
  • Table 78. North America Skin Infection, by by Treatment Type USD Million (2013-2018)
  • Table 79. North America Skin Infection, by by Distribution Channel USD Million (2013-2018)
  • Table 80. United States Skin Infection, by Type USD Million (2013-2018)
  • Table 81. United States Skin Infection, by by Treatment Type USD Million (2013-2018)
  • Table 82. United States Skin Infection, by by Distribution Channel USD Million (2013-2018)
  • Table 83. Canada Skin Infection, by Type USD Million (2013-2018)
  • Table 84. Canada Skin Infection, by by Treatment Type USD Million (2013-2018)
  • Table 85. Canada Skin Infection, by by Distribution Channel USD Million (2013-2018)
  • Table 86. Mexico Skin Infection, by Type USD Million (2013-2018)
  • Table 87. Mexico Skin Infection, by by Treatment Type USD Million (2013-2018)
  • Table 88. Mexico Skin Infection, by by Distribution Channel USD Million (2013-2018)
  • Table 89. Company Basic Information, Sales Area and Its Competitors
  • Table 90. Company Basic Information, Sales Area and Its Competitors
  • Table 91. Company Basic Information, Sales Area and Its Competitors
  • Table 92. Company Basic Information, Sales Area and Its Competitors
  • Table 93. Company Basic Information, Sales Area and Its Competitors
  • Table 94. Company Basic Information, Sales Area and Its Competitors
  • Table 95. Company Basic Information, Sales Area and Its Competitors
  • Table 96. Company Basic Information, Sales Area and Its Competitors
  • Table 97. Skin Infection: by Type(USD Million)
  • Table 98. Skin Infection Bacterial Skin Infection , by Region USD Million (2019-2024)
  • Table 99. Skin Infection Viral Skin Infection , by Region USD Million (2019-2024)
  • Table 100. Skin Infection Fungal Skin Infection , by Region USD Million (2019-2024)
  • Table 101. Skin Infection Parasitic Skin Infection , by Region USD Million (2019-2024)
  • Table 102. South America Skin Infection, by Country USD Million (2019-2024)
  • Table 103. South America Skin Infection, by Type USD Million (2019-2024)
  • Table 104. South America Skin Infection, by by Treatment Type USD Million (2019-2024)
  • Table 105. South America Skin Infection, by by Distribution Channel USD Million (2019-2024)
  • Table 106. Brazil Skin Infection, by Type USD Million (2019-2024)
  • Table 107. Brazil Skin Infection, by by Treatment Type USD Million (2019-2024)
  • Table 108. Brazil Skin Infection, by by Distribution Channel USD Million (2019-2024)
  • Table 109. Argentina Skin Infection, by Type USD Million (2019-2024)
  • Table 110. Argentina Skin Infection, by by Treatment Type USD Million (2019-2024)
  • Table 111. Argentina Skin Infection, by by Distribution Channel USD Million (2019-2024)
  • Table 112. Rest of South America Skin Infection, by Type USD Million (2019-2024)
  • Table 113. Rest of South America Skin Infection, by by Treatment Type USD Million (2019-2024)
  • Table 114. Rest of South America Skin Infection, by by Distribution Channel USD Million (2019-2024)
  • Table 115. Asia Pacific Skin Infection, by Country USD Million (2019-2024)
  • Table 116. Asia Pacific Skin Infection, by Type USD Million (2019-2024)
  • Table 117. Asia Pacific Skin Infection, by by Treatment Type USD Million (2019-2024)
  • Table 118. Asia Pacific Skin Infection, by by Distribution Channel USD Million (2019-2024)
  • Table 119. China Skin Infection, by Type USD Million (2019-2024)
  • Table 120. China Skin Infection, by by Treatment Type USD Million (2019-2024)
  • Table 121. China Skin Infection, by by Distribution Channel USD Million (2019-2024)
  • Table 122. Japan Skin Infection, by Type USD Million (2019-2024)
  • Table 123. Japan Skin Infection, by by Treatment Type USD Million (2019-2024)
  • Table 124. Japan Skin Infection, by by Distribution Channel USD Million (2019-2024)
  • Table 125. India Skin Infection, by Type USD Million (2019-2024)
  • Table 126. India Skin Infection, by by Treatment Type USD Million (2019-2024)
  • Table 127. India Skin Infection, by by Distribution Channel USD Million (2019-2024)
  • Table 128. South Korea Skin Infection, by Type USD Million (2019-2024)
  • Table 129. South Korea Skin Infection, by by Treatment Type USD Million (2019-2024)
  • Table 130. South Korea Skin Infection, by by Distribution Channel USD Million (2019-2024)
  • Table 131. Taiwan Skin Infection, by Type USD Million (2019-2024)
  • Table 132. Taiwan Skin Infection, by by Treatment Type USD Million (2019-2024)
  • Table 133. Taiwan Skin Infection, by by Distribution Channel USD Million (2019-2024)
  • Table 134. Australia Skin Infection, by Type USD Million (2019-2024)
  • Table 135. Australia Skin Infection, by by Treatment Type USD Million (2019-2024)
  • Table 136. Australia Skin Infection, by by Distribution Channel USD Million (2019-2024)
  • Table 137. Rest of Asia-Pacific Skin Infection, by Type USD Million (2019-2024)
  • Table 138. Rest of Asia-Pacific Skin Infection, by by Treatment Type USD Million (2019-2024)
  • Table 139. Rest of Asia-Pacific Skin Infection, by by Distribution Channel USD Million (2019-2024)
  • Table 140. Europe Skin Infection, by Country USD Million (2019-2024)
  • Table 141. Europe Skin Infection, by Type USD Million (2019-2024)
  • Table 142. Europe Skin Infection, by by Treatment Type USD Million (2019-2024)
  • Table 143. Europe Skin Infection, by by Distribution Channel USD Million (2019-2024)
  • Table 144. Germany Skin Infection, by Type USD Million (2019-2024)
  • Table 145. Germany Skin Infection, by by Treatment Type USD Million (2019-2024)
  • Table 146. Germany Skin Infection, by by Distribution Channel USD Million (2019-2024)
  • Table 147. France Skin Infection, by Type USD Million (2019-2024)
  • Table 148. France Skin Infection, by by Treatment Type USD Million (2019-2024)
  • Table 149. France Skin Infection, by by Distribution Channel USD Million (2019-2024)
  • Table 150. Italy Skin Infection, by Type USD Million (2019-2024)
  • Table 151. Italy Skin Infection, by by Treatment Type USD Million (2019-2024)
  • Table 152. Italy Skin Infection, by by Distribution Channel USD Million (2019-2024)
  • Table 153. United Kingdom Skin Infection, by Type USD Million (2019-2024)
  • Table 154. United Kingdom Skin Infection, by by Treatment Type USD Million (2019-2024)
  • Table 155. United Kingdom Skin Infection, by by Distribution Channel USD Million (2019-2024)
  • Table 156. Netherlands Skin Infection, by Type USD Million (2019-2024)
  • Table 157. Netherlands Skin Infection, by by Treatment Type USD Million (2019-2024)
  • Table 158. Netherlands Skin Infection, by by Distribution Channel USD Million (2019-2024)
  • Table 159. Rest of Europe Skin Infection, by Type USD Million (2019-2024)
  • Table 160. Rest of Europe Skin Infection, by by Treatment Type USD Million (2019-2024)
  • Table 161. Rest of Europe Skin Infection, by by Distribution Channel USD Million (2019-2024)
  • Table 162. MEA Skin Infection, by Country USD Million (2019-2024)
  • Table 163. MEA Skin Infection, by Type USD Million (2019-2024)
  • Table 164. MEA Skin Infection, by by Treatment Type USD Million (2019-2024)
  • Table 165. MEA Skin Infection, by by Distribution Channel USD Million (2019-2024)
  • Table 166. Middle East Skin Infection, by Type USD Million (2019-2024)
  • Table 167. Middle East Skin Infection, by by Treatment Type USD Million (2019-2024)
  • Table 168. Middle East Skin Infection, by by Distribution Channel USD Million (2019-2024)
  • Table 169. Africa Skin Infection, by Type USD Million (2019-2024)
  • Table 170. Africa Skin Infection, by by Treatment Type USD Million (2019-2024)
  • Table 171. Africa Skin Infection, by by Distribution Channel USD Million (2019-2024)
  • Table 172. North America Skin Infection, by Country USD Million (2019-2024)
  • Table 173. North America Skin Infection, by Type USD Million (2019-2024)
  • Table 174. North America Skin Infection, by by Treatment Type USD Million (2019-2024)
  • Table 175. North America Skin Infection, by by Distribution Channel USD Million (2019-2024)
  • Table 176. United States Skin Infection, by Type USD Million (2019-2024)
  • Table 177. United States Skin Infection, by by Treatment Type USD Million (2019-2024)
  • Table 178. United States Skin Infection, by by Distribution Channel USD Million (2019-2024)
  • Table 179. Canada Skin Infection, by Type USD Million (2019-2024)
  • Table 180. Canada Skin Infection, by by Treatment Type USD Million (2019-2024)
  • Table 181. Canada Skin Infection, by by Distribution Channel USD Million (2019-2024)
  • Table 182. Mexico Skin Infection, by Type USD Million (2019-2024)
  • Table 183. Mexico Skin Infection, by by Treatment Type USD Million (2019-2024)
  • Table 184. Mexico Skin Infection, by by Distribution Channel USD Million (2019-2024)
  • Table 185. Research Programs/Design for This Report
  • Table 186. Key Data Information from Secondary Sources
  • Table 187. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Skin Infection: by Type USD Million (2013-2018)
  • Figure 5. South America Skin Infection Share (%), by Country
  • Figure 6. Asia Pacific Skin Infection Share (%), by Country
  • Figure 7. Europe Skin Infection Share (%), by Country
  • Figure 8. MEA Skin Infection Share (%), by Country
  • Figure 9. North America Skin Infection Share (%), by Country
  • Figure 10. Global Skin Infection share by Players 2018 (%)
  • Figure 11. Global Skin Infection share by Players (Top 3) 2018(%)
  • Figure 12. Global Skin Infection share by Players (Top 5) 2018(%)
  • Figure 13. BCG Matrix for key Companies
  • Figure 14. 3M Company (United States) Revenue, Net Income and Gross profit
  • Figure 15. 3M Company (United States) Revenue: by Geography 2018
  • Figure 16. B. Braun Melsungen (Germany) Revenue, Net Income and Gross profit
  • Figure 17. B. Braun Melsungen (Germany) Revenue: by Geography 2018
  • Figure 18. Coloplast (Denmark) Revenue, Net Income and Gross profit
  • Figure 19. Coloplast (Denmark) Revenue: by Geography 2018
  • Figure 20. Genzyme Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 21. Genzyme Corporation (United States) Revenue: by Geography 2018
  • Figure 22. Smith & Nephew (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 23. Smith & Nephew (United Kingdom) Revenue: by Geography 2018
  • Figure 24. ConvaTec Healthcare (United States) Revenue, Net Income and Gross profit
  • Figure 25. ConvaTec Healthcare (United States) Revenue: by Geography 2018
  • Figure 26. Human Biosciences Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 27. Human Biosciences Inc. (United States) Revenue: by Geography 2018
  • Figure 28. Melinta Therapeutics, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 29. Melinta Therapeutics, Inc. (United States) Revenue: by Geography 2018
  • Figure 30. Global Skin Infection: by Type USD Million (2019-2024)
  • Figure 31. South America Skin Infection Share (%), by Country
  • Figure 32. Asia Pacific Skin Infection Share (%), by Country
  • Figure 33. Europe Skin Infection Share (%), by Country
  • Figure 34. MEA Skin Infection Share (%), by Country
  • Figure 35. North America Skin Infection Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • 3M Company (United States)
  • B. Braun Melsungen (Germany)
  • Coloplast (Denmark)
  • Genzyme Corporation (United States)
  • Smith & Nephew (United Kingdom)
  • ConvaTec Healthcare (United States)
  • Human Biosciences Inc. (United States)
  • Melinta Therapeutics, Inc. (United States)
Additional players considered in the study are as follows:
Merck & Co., Inc. (United States) , Allergan plc (United States) , Accord Healthcare Ltd. (United Kingdom)
Select License Type
Sample Report Enquiry Before Buy Request Discount
Slider
Slider
Slider
DOWNLOAD SAMPLE PDF

Speak with Analyst

Want to find out more about this report?

Get Free Consultation
Ask a Question!

Related Reports

Influenza Vaccines Comprehensive Study by Type (Paediatrics, Adolescence, Adults, Elderly), Application (Hospitals, Clinics, Others), Technology (Egg Based, Cell Culture, Recombinant), Vaccines (Fluz...
Influenza Vaccines Comprehensive Study by Type (Paediatrics, Adolescence, Adults, Elderly), Application (Hospitals, Clinics, Others), Technology (Egg Based, Cell Culture, Recombinant), Vaccines (Fluz...
$ 3800
Paediatric Vaccine Comprehensive Study by Type (Pneumococcal, Varicella, Combinations, Poliovirus, Hepatitis , MMR , Pediatric Hormones , HIB, Allergy and Respiratory vaccines, Other Pediatric vaccin...
Paediatric Vaccine Comprehensive Study by Type (Pneumococcal, Varicella, Combinations, Poliovirus, Hepatitis , MMR , Pediatric Hormones , HIB, Allergy and Respiratory vaccines, Other Pediatric vaccin...
$ 3800
Microbiome Therapeutics Comprehensive Study by Type (FMT, Microbiome drugs), Indication (Type 2 diabetes, Obesity, C. difficile Infection, Primary Hyperoxyurea), Technology (Sequencing, Genomic Techn...
Microbiome Therapeutics Comprehensive Study by Type (FMT, Microbiome drugs), Indication (Type 2 diabetes, Obesity, C. difficile Infection, Primary Hyperoxyurea), Technology (Sequencing, Genomic Techn...
$ 3800
Liver Fibrosis Drug Comprehensive Study by Type (Interferon, Maloti Lipid, Nucleoside, Other), Application (Hospital, Clinic, Research Center), Diagnosis (Liver Biopsy, Transient Elastography, Nonsur...
Liver Fibrosis Drug Comprehensive Study by Type (Interferon, Maloti Lipid, Nucleoside, Other), Application (Hospital, Clinic, Research Center), Diagnosis (Liver Biopsy, Transient Elastography, Nonsur...
$ 3800
Salivary Gland Cancer Comprehensive Study by Type (Parotid glands, Submandibular glands, Sublingual glands), Application (Hospitals & clinics, Medical research centers, Academic institutes, Others), ...
Salivary Gland Cancer Comprehensive Study by Type (Parotid glands, Submandibular glands, Sublingual glands), Application (Hospitals & clinics, Medical research centers, Academic institutes, Others), ...
$ 3800
Malabsorption Syndrome Comprehensive Study by Application (Pharmaceutical Companies, Hospitals, Nutrition Clinics, Academic And Research Institutes), Treatment (Nutritional Supplements, Gluten-Free D...
Malabsorption Syndrome Comprehensive Study by Application (Pharmaceutical Companies, Hospitals, Nutrition Clinics, Academic And Research Institutes), Treatment (Nutritional Supplements, Gluten-Free D...
$ 3800